Strategies for Optimal HIV Treatment and Prevention

In this case example, learn data and recommendations for considering a switch to long-acting CAB plus RPV, including current indications and contraindications, data for “direct to inject” without an oral lead-in, and considerations for dosing every 8 weeks vs every 4 weeks.

Darcy Wooten, MD Released: July 22, 2022

See data and recommendations for considering a switch to long-acting CAB plus RPV, including current indications and contraindications, data for “direct to inject” without an oral lead-in, and considerations for dosing every 8 weeks vs every 4 weeks.

Darcy Wooten, MD Released: September 16, 2022

A patient shares his experiences with switching from daily oral to long-acting antiretroviral therapy and how the change in treatment regimen better met his needs.

Anonymous Patient Released: August 30, 2022

Hear from expert faculty as they answer questions and discuss key considerations when determining whether and how to switch antiretroviral therapy in virologically suppressed individuals with HIV.

Tristan J. Barber, MA, MD, FRCP Darcy Wooten, MD Released: October 19, 2022

In this case example, learn data and recommendations for considering an ART switch following weight gain, including what is known about ART-associated weight gain and resulting metabolic complications, what the data are for switching, and what the guidelines recommend in this scenario.

Darcy Wooten, MD Released: August 1, 2022

See data and recommendations for considering an ART switch following weight gain, including what is known about ART-associated weight gain and resulting metabolic complications, what the data are for switching, and what the guidelines recommend in this scenario.

Darcy Wooten, MD Released: October 21, 2022

I’m doing really well on my current ART regimen, with the exception of the weight gain that I’ve recently noticed. I will manage my weight gain with lifestyle changes for now, and here are my reasons.

Anonymous Patient Released: September 8, 2022

Should you continue or switch ART for someone who becomes pregnant while virologically suppressed on a bictegravir-containing regimen? In this case example, learn about available data and recommendations for the use of bictegravir in pregnancy, as well as key considerations for deciding whether to switch ART for someone who becomes pregnant while virologically suppressed on a bictegravir-containing regimen.

William R. Short, MD, MPH, AAHIVS Released: September 28, 2022

See available data and recommendations for the use of bictegravir in pregnancy, as well as key considerations for deciding whether to switch ART for someone who becomes pregnant while virologically suppressed on a bictegravir-containing regimen.

William R. Short, MD, MPH, AAHIVS Released: October 20, 2022

Read my take on the factors to consider when contemplating a switch in antiretroviral therapy.

Tristan J. Barber, MA, MD, FRCP Released: October 11, 2022

In this case example, learn about available data and recommendations for the use of long-acting cabotegravir in pregnancy, as well as key considerations for deciding whether to switch ART for someone who becomes pregnant while virologically suppressed on long-acting cabotegravir and rilpivirine.

William R. Short, MD, MPH, AAHIVS Released: September 28, 2022

See available data and recommendations for the use of long-acting cabotegravir in pregnancy, as well as key considerations for deciding whether to switch ART for someone who becomes pregnant while virologically suppressed on long-acting cabotegravir and rilpivirine.

William R. Short, MD, MPH, AAHIVS Released: October 21, 2022

Hear from expert faculty as they answer questions and discuss key considerations when determining whether and how to switch antiretroviral therapy in virologically suppressed individuals with HIV.

Tristan J. Barber, MA, MD, FRCP Darcy Wooten, MD Released: October 11, 2022

We should move from protecting pregnant women from research to protecting them through research. That’s how we can safely provide newer antiretroviral therapy options for people with HIV during pregnancy

Annette Haberl, MD Released: November 2, 2022

The future must provide a way to decrease the therapeutic burden for people with HIV without compromising ART efficacy—improving the overall experience for the patient by doing more with less.

Christine Katlama, MD Released: January 4, 2023

Hear from expert faculty as they answer questions and discuss key considerations when determining whether and how to switch antiretroviral therapy in pregnant people with HIV.

Annette Haberl, MD William R. Short, MD, MPH, AAHIVS Released: November 23, 2022

Hear from expert faculty as they answer questions and discuss key considerations when determining whether and how to switch antiretroviral therapy in pregnant people with HIV.

Annette Haberl, MD William R. Short, MD, MPH, AAHIVS Released: December 19, 2022